|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61P 35/00 | (2006.01) |
| C07D 471/04 | (2006.01) |
| (11) | Number of the document | 4301468 |
| (13) | Kind of document | T |
| (96) | European patent application number | 22712686.9 |
| Date of filing the European patent application | 2022-03-03 | |
| (97) | Date of publication of the European application | 2024-01-10 |
| (45) | Date of publication and mention of the grant of the patent | 2025-09-03 |
| (46) | Date of publication of the claims translation | 2025-12-29 |
| (86) | Number | PCT/US2022/018644 |
| Date | 2022-03-03 |
| (87) | Number | WO 2022/187443 |
| Date | 2022-09-09 |
| (30) | Number | Date | Country code |
| 202163156527 P | 2021-03-04 | US |
| (72) |
ABRAHAM, Adedoyin David , US
BUME, Desta Doro , US
CONDROSKI, Kevin Ronald , US
DILGER, Andrew Karl , US
HAZLITT, Robert Alan , US
KERCHER, Timothy Scott , US
METCALF, Andrew Terrance , US
URKALAN, Kaveri Balan , US
WALLS, Shane Michael , US
|
| (73) |
Eli Lilly and Company ,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
| (74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
| (54) | FGFR3 inhibitorių junginiai |
| FGFR3 INHIBITOR COMPOUNDS |
| Payment date | Validity (years) | Amount | |
| 2026-02-19 | 5 | 115.00 EUR |
| 2027-03-03 |